Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers through GSK-3β inhibition, has announced that its President & CEO, Daniel Schmitt, will ring the Nasdaq opening bell on August 23, 2024. This ceremony marks the company's recent IPO and its new status as a Nasdaq-listed company.
The event, starting at approximately 9:15 am ET, will be held at the Nasdaq MarketSite Tower in New York City. Schmitt will be joined by members of Actuate's team, Board of Directors, Scientific Advisory Board, and guests. The ceremony will be live-streamed on Nasdaq's X and Facebook pages, allowing wider audience participation in this significant corporate milestone.
Actuate Therapeutics, Inc. (NASDAQ: ACTU), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per tumori difficili da trattare attraverso l'inibizione di GSK-3β, ha annunciato che il suo Presidente e CEO, Daniel Schmitt, suonerà la campana di apertura del Nasdaq il 23 agosto 2024. Questa cerimonia segna il recente IPO dell'azienda e il suo nuovo status come azienda quotata al Nasdaq.
L'evento, che avrà inizio intorno alle 9:15 ET, si terrà presso la Nasdaq MarketSite Tower a New York City. Schmitt sarà accompagnato dai membri del team di Actuate, dal Consiglio di Amministrazione, dal Consiglio Scientifico e da ospiti. La cerimonia sarà trasmessa in diretta sulle pagine X e Facebook del Nasdaq, consentendo una maggiore partecipazione del pubblico a questo importante traguardo aziendale.
Actuate Therapeutics, Inc. (NASDAQ: ACTU), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias para cánceres difíciles de tratar mediante la inhibición de GSK-3β, ha anunciado que su Presidente y CEO, Daniel Schmitt, sonará la campana de apertura del Nasdaq el 23 de agosto de 2024. Esta ceremonia marca la reciente OPI de la empresa y su nuevo estatus como empresa cotizada en Nasdaq.
El evento, que comenzará alrededor de las 9:15 a.m. ET, se llevará a cabo en la torre Nasdaq MarketSite en la ciudad de Nueva York. Schmitt estará acompañado por miembros del equipo de Actuate, la Junta Directiva, el Consejo Asesor Científico y invitados. La ceremonia será transmitida en vivo en las páginas de X y Facebook de Nasdaq, permitiendo una mayor participación de la audiencia en este importante hito corporativo.
Actuate Therapeutics, Inc. (NASDAQ: ACTU)는 GSK-3β 억제를 통한 치료가 어려운 암의 치료법 개발에 초점을 맞춘 임상 단계의 생명공학 회사입니다. 이 회사는 사장 겸 CEO인 다니엘 슈미트가 2024년 8월 23일에 나스닥 개장 벨을 울린다고 발표했습니다. 이 행사에서는 회사의 최근 IPO와 나스닥 상장 회사로서의 새로운 지위를 기념합니다.
이 행사는 동부 표준시 기준으로 오전 9시 15분경에 뉴욕 시에 위치한 나스닥 마켓사이트 타워에서 개최될 예정입니다. 슈미트는 Actuate 팀의 구성원, 이사회의 멤버, 과학 자문 위원회, 그리고 손님들과 함께 할 것입니다. 이 행사는 라이브 스트리밍을 통해 나스닥의 X 및 페이스북 페이지에서 중계되어 더 많은 청중이 이 중요한 기업 이정표에 참여할 수 있는 기회를 제공합니다.
Actuate Therapeutics, Inc. (NASDAQ: ACTU), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour les cancers difficiles à traiter via l'inhibition de GSK-3β, a annoncé que son président-directeur général, Daniel Schmitt, sonnera la cloche d'ouverture du Nasdaq le 23 août 2024. Cette cérémonie marque la récente introduction en bourse de la société et son nouveau statut en tant qu'entreprise cotée au Nasdaq.
L'événement, qui commencera vers 9h15 ET, se tiendra à la tour Nasdaq MarketSite à New York. Schmitt sera accompagné par des membres de l'équipe d'Actuate, du Conseil d'Administration, du Conseil Consultatif Scientifique et des invités. La cérémonie sera diffusée en direct sur les pages X et Facebook de Nasdaq, permettant une plus large participation du public à cette étape importante pour l'entreprise.
Actuate Therapeutics, Inc. (NASDAQ: ACTU), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für schwer behandelbare Krebsarten durch GSK-3β-Hemmung konzentriert, hat bekannt gegeben, dass sein Präsident und CEO, Daniel Schmitt, am 23. August 2024 die Nasdaq-Öffnungsglocke läuten wird. Diese Zeremonie markiert den jüngsten Börsengang des Unternehmens und seinen neuen Status als an der Nasdaq gelistetes Unternehmen.
Die Veranstaltung, die um etwa 9:15 Uhr ET beginnt, findet im Nasdaq MarketSite Tower in New York City statt. Schmitt wird von Mitgliedern des Actuate-Teams, dem Vorstand, dem Wissenschaftlichen Beratungsrat und Gästen begleitet. Die Zeremonie wird live gestreamt auf den X- und Facebook-Seiten von Nasdaq, um einer breiteren Öffentlichkeit die Teilnahme an diesem wichtigen Unternehmensmeilenstein zu ermöglichen.
- Successful completion of Initial Public Offering (IPO)
- Listing on Nasdaq, potentially increasing visibility and access to capital
- None.
CHICAGO and FORT WORTH, Texas, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Office will ring the Nasdaq Stock Market (Nasdaq) opening bell on August 23, 2024, in New York City.
“We are thrilled to celebrate our IPO by ringing the Nasdaq opening bell – a major corporate milestone made possible by the unwavering support of our investors, partners, and our dedicated team,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “The ceremony symbolizes the beginning of an exciting new chapter for Actuate and we look forward to our journey as a Nasdaq-listed company.”
Daniel Schmitt, President & Chief Executive Office of Actuate, will be joined by other members of the Actuate’s team, Board of Directors, Scientific Advisory Board members, and guests, at the ceremony which will begin at approximately 9.15 am ET. The event will be live-streamed from the Nasdaq MarketSite Tower in New York and available on Nasdaq’s X and Facebook pages.
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements about us and our industry. The forward-looking statements involve substantial risks and uncertainties, including those described under “Risk Factors” in Actuate’s Registration Statement. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Risk Factors” in the Registration Statement.
You should assume that the information appearing in this press release is accurate as of its date only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
FAQ
When will Actuate Therapeutics (ACTU) ring the Nasdaq opening bell?
What is the focus of Actuate Therapeutics' (ACTU) drug development?
How can investors watch Actuate Therapeutics' (ACTU) Nasdaq bell ringing ceremony?
What does the Nasdaq bell ringing ceremony signify for Actuate Therapeutics (ACTU)?
